MINORYX THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR LERIGLITAZONE IN FRIEDREICH’S ATAXIA

17 October, 2019.
Mataró, Barcelona, Spain and Charleroi, Belgium, October 17, 2019 – Minoryx Therapeutics, a company that specializes in the development of innovative treatments for orphan Central Nervous System (CNS) diseases, today announces that its lead drug candidate, leriglitazone (MIN-102), has been granted Orphan Drug Designation in Friedreich’s Ataxia by the US Food and Drug Administration (FDA).

MINORYX THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR LERIGLITAZONE IN FRIEDREICH’S ATAXIA